Summary Basis of Decision (SBD) for Giotrif

Health Canada has issued a Notice of Compliance to Boehringer Ingelheim (Canada) Ltd. for the drug product, Giotrif. Based on Health Canada's review, the benefit/risk profile of Giotrif is favourable as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor-naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of the lung with activating EGFR mutation(s). Read more here.